So if I look at where we are today, the two products we just talked about are very different ... that will add additional $20 billion to the top line by the mid-2030s. So we're also looking to do the ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

(Reuters) - A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the ...

Over more than 20 years in the pharma industry ... and to direct R&D efforts where they can best help patients. To achieve this objective, in 2017, Merck launched a first-of-its-kind initiative ...

Given this outlook, focusing on high-yield dividend stocks and cautious valuation is essential for long-term investment ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

With Johnson & Johnson (NYSE:JNJ) taking the lead, Big Pharma returned to dealmaking in H1 2024 even as the number of M&A ...

We recently compiled a list of the 10 Best Fortune 500 Stocks To Buy Now. In this article, we are going to take a look at ...

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are ...

Although neither customers nor companies like them, recalls are more prevalent than people realize. Companies make mistakes ...